Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K.

JAMA Oncol. 2019 Aug 15:e191870. doi: 10.1001/jamaoncol.2019.1870. [Epub ahead of print]

PMID:
31415071
2.

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.

Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S.

Br J Cancer. 2019 Aug 13. doi: 10.1038/s41416-019-0548-9. [Epub ahead of print]

PMID:
31406299
3.

Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ.

J Natl Cancer Inst. 2019 May 20. pii: djz093. doi: 10.1093/jnci/djz093. [Epub ahead of print]

PMID:
31322663
4.

Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.

Willis JA, Overman MJ, Vilar E.

Clin Cancer Res. 2019 Jul 1. doi: 10.1158/1078-0432.CCR-19-1447. [Epub ahead of print]

PMID:
31263028
5.

Immunotherapy in colorectal cancer with mismatch repair deficiency.

Overman MJ.

Clin Adv Hematol Oncol. 2019 May;17(5):265-267. No abstract available.

PMID:
31188802
6.

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.

Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B.

Oncologist. 2019 May 30. pii: theoncologist.2019-0129. doi: 10.1634/theoncologist.2019-0129. [Epub ahead of print]

PMID:
31147488
7.

Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management.

Lieu CH, Corcoran RB, Overman MJ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:207-215. doi: 10.1200/EDBK_240839. Epub 2019 May 17.

PMID:
31099678
8.

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA.

Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21.

PMID:
30905761
9.

Clinical and molecular characterization of early-onset colorectal cancer.

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM.

Cancer. 2019 Jun 15;125(12):2002-2010. doi: 10.1002/cncr.31994. Epub 2019 Mar 11.

PMID:
30854646
10.

Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S.

Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. doi: 10.1007/s11894-019-0674-9. Review.

11.

On the underreporting of health-related quality of life and regulatory approval.

Bhamidipati D, Anand S, Gothwal A, Raghav K, Overman MJ.

Ann Oncol. 2019 Apr 1;30(4):657-658. doi: 10.1093/annonc/mdz033. No abstract available.

PMID:
30698646
12.

Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.

Aldrich JD, Raghav KPS, Varadhachary GR, Wolff RA, Overman MJ.

Oncologist. 2019 Jun;24(6):e384-e386. doi: 10.1634/theoncologist.2018-0573. Epub 2018 Dec 31.

PMID:
30598498
13.

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.

Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ.

BMC Med Res Methodol. 2018 Dec 12;18(1):169. doi: 10.1186/s12874-018-0627-2.

14.

Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit.

Ko H, Yan M, Gupta R, Kebbel K, Maiti A, Song J, Nates J, Overman MJ.

Oncologist. 2019 Apr;24(4):483-490. doi: 10.1634/theoncologist.2018-0328. Epub 2018 Dec 5.

PMID:
30518614
15.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
16.

Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury.

Mizrahi JD, Overman MJ.

Oncotarget. 2018 Oct 9;9(79):34857-34858. doi: 10.18632/oncotarget.26207. eCollection 2018 Oct 9. No abstract available.

17.

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology.

Parseghian CM, Tam AL, Yao J, Ensor J Jr, Ellis LM, Raghav K, Overman MJ.

JAMA Oncol. 2019 Mar 1;5(3):402-405. doi: 10.1001/jamaoncol.2018.4640.

PMID:
30383128
18.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ.

Clin Cancer Res. 2019 Jan 15;25(2):641-651. doi: 10.1158/1078-0432.CCR-18-1480. Epub 2018 Oct 23.

PMID:
30352910
19.

Facile profiling of molecular heterogeneity by microfluidic digital melt.

O'Keefe CM, Pisanic TR 2nd, Zec H, Overman MJ, Herman JG, Wang TH.

Sci Adv. 2018 Sep 28;4(9):eaat6459. doi: 10.1126/sciadv.aat6459. eCollection 2018 Sep.

20.

Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.

Overman MJ, Ernstoff MS, Morse MA.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:239-247. doi: 10.1200/EDBK_200821. Review.

PMID:
30231358
21.

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.

Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S.

Clin Colorectal Cancer. 2018 Dec;17(4):e699-e709. doi: 10.1016/j.clcc.2018.07.005. Epub 2018 Jul 17.

22.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S.

Ann Oncol. 2019 Mar 1;30(3):495. doi: 10.1093/annonc/mdy221. No abstract available.

23.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

24.

Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials.

Overman MJ, Ellis LM, Joffe S.

JAMA Oncol. 2018 Aug 1;4(8):1041-1042. doi: 10.1001/jamaoncol.2018.1002. No abstract available.

PMID:
29799989
25.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG.

Front Oncol. 2018 Apr 20;8:107. doi: 10.3389/fonc.2018.00107. eCollection 2018. Review.

26.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Dec 1;110(12):1409-1417. doi: 10.1093/jnci/djy067.

27.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

28.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Mehrvarz Sarshekeh A, Overman MJ, Kopetz S.

Future Oncol. 2018 Aug;14(18):1869-1874. doi: 10.2217/fon-2017-0696. Epub 2018 Feb 23. Review.

29.

Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.

Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ.

Cancer. 2018 Apr 15;124(8):1701-1709. doi: 10.1002/cncr.31251. Epub 2018 Jan 25.

30.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
31.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
32.

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ.

Oncologist. 2018 Mar;23(3):277-e26. doi: 10.1634/theoncologist.2017-0568. Epub 2017 Dec 19.

33.

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e103-e108. doi: 10.1016/j.clml.2017.11.001. Epub 2017 Nov 14.

PMID:
29196178
34.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

35.

Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.

Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S.

Gut. 2018 Jun;67(6):1095-1102. doi: 10.1136/gutjnl-2017-313786. Epub 2017 Oct 30.

PMID:
29084828
36.

Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?

Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Marchal F, Conrad C, Aloia TA, Vauthey JN, Chun YS; BIG-RENAPE Working Group.

Ann Surg Oncol. 2018 Jan;25(1):179-187. doi: 10.1245/s10434-017-6141-7. Epub 2017 Oct 25.

PMID:
29071660
37.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R 2nd, Azad N, Kopetz S.

Ann Oncol. 2018 Jan 1;29(1):139-144. doi: 10.1093/annonc/mdx688. Erratum in: Ann Oncol. 2019 Mar 1;30(3):495.

38.

Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma.

Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C.

Ann Surg Oncol. 2017 Dec;24(13):3954-3963. doi: 10.1245/s10434-017-6098-6. Epub 2017 Oct 4.

39.

Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade.

Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

World J Gastrointest Oncol. 2017 Sep 15;9(9):354-362. doi: 10.4251/wjgo.v9.i9.354.

40.

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C.

Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25.

41.

Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm.

Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ.

Ann Surg Oncol. 2017 Nov;24(12):3667-3672. doi: 10.1245/s10434-017-6052-7. Epub 2017 Aug 22.

PMID:
28831698
42.

Underreporting of Research Biopsies from Clinical Trials in Oncology.

Parseghian CM, Raghav K, Wolff RA, Ensor J Jr, Yao J, Ellis LM, Tam AL, Overman MJ.

Clin Cancer Res. 2017 Nov 1;23(21):6450-6457. doi: 10.1158/1078-0432.CCR-17-1449. Epub 2017 Jul 28.

43.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.

44.

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG.

JAMA Surg. 2017 Nov 1;152(11):1048-1056. doi: 10.1001/jamasurg.2017.2227.

45.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.

Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF.

Ann Surg Oncol. 2017 Sep;24(9):2646-2654. doi: 10.1245/s10434-017-5938-8. Epub 2017 Jul 10.

PMID:
28695394
46.

Genomic Profiling of Small-Bowel Adenocarcinoma.

Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ.

JAMA Oncol. 2017 Nov 1;3(11):1546-1553. doi: 10.1001/jamaoncol.2017.1051.

47.

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.

Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ.

BMC Cancer. 2017 May 15;17(1):331. doi: 10.1186/s12885-017-3327-0.

48.

Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside?

Vauthey JN, Mizuno T, Overman MJ, Soubrane O.

J Hepatol. 2017 Jul;67(1):10-11. doi: 10.1016/j.jhep.2017.04.011. Epub 2017 May 3. No abstract available.

PMID:
28476639
49.

Modeling of Patient-Derived Xenografts in Colorectal Cancer.

Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S.

Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.

50.

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.

Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A.

Oncotarget. 2017 Jun 13;8(24):39268-39279. doi: 10.18632/oncotarget.16848.

Supplemental Content

Loading ...
Support Center